Analyst Price Targets — ENTA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 23, 2026 10:52 am | Brandon Folkes | H.C. Wainwright | $20.00 | $13.37 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA) |
| October 1, 2025 2:21 pm | Akash Tewari | Jefferies | $20.00 | $10.88 | TheFly | Enanta upgraded to Buy from Hold at Jefferies |
| June 3, 2025 9:37 am | Roy Buchanan | JMP Securities | $24.00 | $7.19 | TheFly | Enanta price target raised to $24 from $23 at Citizens JMP |
| December 9, 2022 6:10 am | — | H.C. Wainwright | $56.00 | $41.96 | Benzinga | HC Wainwright & Co. Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $56 |
| November 22, 2022 7:39 am | — | RBC Capital | $54.00 | $46.40 | Benzinga | RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54 |
| July 29, 2022 10:32 am | Yasmeen Rahimi | Piper Sandler | $87.00 | $51.28 | TheFly | Enanta's 'strong' EDP-235 data supports 'impressive' profile, says Piper Sandler |
Latest News for ENTA
[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September: Baird 2026 Global Healthcare Conference: Fireside Chat on Tuesday, September 15, 2026 at 1:25 p.m. ET H.C.…
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.85 per share a year ago.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026. “During the quarter, we continued to build momentum across both our RSV and immunology programs,” said Jay R. Luly, Ph.D.,…
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ENTA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.